首页 | 官方网站   微博 | 高级检索  
     


Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
Authors:Jasmin Bahlo  Sandra Kluth  Christina Rhein  Paula Cramer  Carolin Gross‐Ophoff  Petra Langerbeins  Anna‐Maria Fink  Barbara Eichhorst  Karl‐Anton Kreuzer  Norbert Fischer  Eugen Tausch  Stephan Stilgenbauer  Sebastian Böttcher  Hartmut Döhner  Michael Kneba  Martin Dreyling  Mascha Binder  Michael Hallek  Clemens‐Martin Wendtner  the German CLL Study Group
Affiliation:1. Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany;2. Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany;3. Department of Internal Medicine III, University of Ulm, Ulm, Germany;4. Second Department of Medicine, University Hospital of Schleswig‐Holstein, Campus Kiel, Kiel, Germany;5. Department of Medicine III, Hospital of the University LMU München, München, Germany;6. Department of Oncology and Hematology, BMT with Section Pneumology, Hubertus Wald Tumorzentrum/UVVH, University Medical Center Hamburg‐Eppendorf, Hamburg, Germany;7. Department I of Internal Medicine, Center of Integrated Oncology K?ln Bonn, Cluster of Excellence on “Cellular Stress Responses in Aging” (CECAD), University of Cologne, Cologne, Germany
Abstract:
Keywords:combination treatment with lenalidomide  dose levels  dose limiting toxicity  overall response rate  toxicity
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号